Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody

Haemophilia

Volumn 16, Issue 102, 2010, Pages 16-19

  Jacquemin, M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Factor VIII; Glycosylation; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9; LONG ACTING DRUG; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LE2E9; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTICOAGULATION; ANTIGEN BINDING; ARTICLE; BINDING SITE; DEGLYCOSYLATION; DRUG EFFICACY; GENE MUTATION; GLYCOSYLATION; HEART ATRIUM FIBRILLATION; HEMOPHILIA A; HUMAN; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; THROMBOPHILIA; THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR VIII; FIBRINOLYTIC AGENTS; GLYCOSYLATION; HEMOPHILIA A; HUMANS; MICE; THROMBOSIS;

EID: 77953196497     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02233.x     Document Type: Article

References (21)

1. Hoyer LW, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin Hematol 1994, 31:1-5.
2. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982, 60:1103-9.
3. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996, 271:27424-31.
4. Gilles JG, Lavend'homme R, Peerlinck K. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-VWF complexes. Thromb Haemost 1999, 82:40-5.
5. Gilles JG, Arnout J, Vermylen J, Saint-Remy JMR. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993, 82:2452-61.
6. Sultan Y, Kazatchkine M, Maisonneuve P, Nydegger U. Anti-idiotypic suppression of auto-antibodies to factor VIII (anti-hemophilic factor) by high dose intravenous gammaglobulin. Lancet 1984, 2:765-8.
7. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994, 94:1496-505.
8. Jacquemin MG, Desqueper BG, Benhida A. Mechanisms and kinetics of fVIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998, 92:496-506.
9. Peerlinck K, Jacquemin M, Arnout J. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999, 93:2267-73.
10. Hay CR, Ludlam CA, Colvin BT. Factor VIII inhibitors in Mild and Moderate-severity Haemophilia A. Thromb Haemost 1998, 79:762-6.
11. Vlot A, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost 1998, 79:456-65.
12. Kaufman RJ. Post-translational modifications required for coagulation factor secretion and function. Thromb Haemost 1998, 79:1068-79.
13. Jacquemin M, Benhida A, Peerlinck K. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000, 95:156-63.
14. Gilbert GE, Novakovic V, Cullinan DB, Jacquemin M. Inhibitor antibody LE2E9 against factor VIII C1 domain inhibits phospholipid binding and alters factor Xase enzyme complex formation. J Thromb Haemost 2007, 5(Suppl. 2):P-S-042.
15. Hamer RJ, Koedam JA, Beeser-Visser NH, Bertina RM, Van Mourik JA, Sixma JJ. Factor VIII binds to von Willebrand factor via its Mr 80,000 light chain. Eur J Biochem 1987, 166:37-43.
16. Shima M, Scandella D, Yoshioka A. Factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993, 69:240-6.
17. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994, 269:11601-5.
18. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990, 75:1999-2004.
19. Jacquemin M, Radcliffe CM, Lavend'homme R. Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody. J Thromb Haemost 2006, 4:1047-55.
20. Dewerchin M, Van der Elst L, Singh I. Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice. J Thromb Haemost 2004, 2:77-84.
21. Srámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003, 362:351-4.